

Antithrombin Activity, Plasma

Patient ID SA00084140	Patient Name SAMPLEREPORT, ATTF		Birth Date 1984-06-07	Gender M	Age 32
Order Number SA00084140	Client Order Number SA00084140	Ordering Physician CLIENT, CLIENT	Report Notes		
Account Information C7028846 DLMP Rochest	ter	Collected 08 Jan 2017 13:00			

Antithrombin Activity, P

Result Name	Value	Unit	Reference Value	Performing Site
Antithrombin Activity, P	102	%	80–130	1 MCR

Direct factor Xa inhibitor therapy (rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa)) may interfere with the functional Xa based AT assay and cause an overestimation of AT activity thus potentially masking diagnosis of AT deficiency. Suggest clinical correlation and consider repeat AT testing remote from direct factor Xa inhibitor therapy, if clinically indicated.

Received: 09 Jan 2017 11:41 Reported: 09 Jan 2017 11:42

Laboratory Notes

1 This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292